-+ 0.00%
-+ 0.00%
-+ 0.00%
Sellas Life Sciences Presents Phase 3 Data Showing GPS Reduces Death Risk 41% in AML Patients
Share
Listen to the news
Sellas Life Sciences Presents Phase 3 Data Showing GPS Reduces Death Risk 41% in AML Patients
  • Sellas Life Sciences' galinpepimut-S met the Phase 3 REGAL trial's primary endpoint, reducing death risk by 41% in AML patients in second remission.
  • Median overall survival reached 24.0 months with galinpepimut-S versus 14.7 months with best available treatment.
  • The hazard ratio was 0.59, with statistical significance at p=0.035.
  • The company plans to meet with the FDA while preparing an expedited biologics license application for galinpepimut-S.
  • SLS009 also met all primary endpoints in its completed Phase 2 study in relapsed or refractory AML.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief on November 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending